Taro Pharmaceutical Industries Ltd. logo
Taro Pharmaceutical Industries Ltd. TARO

Annual report 2022
added 07-25-2022

report update icon

Taro Pharmaceutical Industries Ltd. Total Assets 2011-2026 | TARO

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Taro Pharmaceutical Industries Ltd.

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
2.18 B 2.41 B 2.34 B 2.14 B 2.43 B 2.29 B 2.19 B 1.74 B 1.28 B 1.11 B 856 M 796 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
2.43 B 796 M 1.81 B

Quarterly Total Assets Taro Pharmaceutical Industries Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - - - 2.41 B - - - 2.34 B - - - 2.14 B - - - 2.43 B - - - 2.29 B - - - 2.19 B - - - 1.74 B - - - 1.28 B - - - 1.11 B - - - 856 M 796 M - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
2.43 B 796 M 1.78 B

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
AbbVie AbbVie
ABBV
134 B $ 209.63 -0.71 % $ 371 B usaUSA
Verastem Verastem
VSTM
246 M $ 4.99 -5.77 % $ 346 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
84.3 M $ 0.57 -5.85 % $ 17.6 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
35.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
6.95 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
47.1 M - 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
151 M - 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
302 M - -0.23 % $ 916 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
252 M $ 3.96 -4.24 % $ 232 M usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
24.2 M - 10.36 % $ 9.8 M usaUSA
Aptinyx Aptinyx
APTX
66.7 M - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
785 M - -6.81 % $ 3.04 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
2.67 M - -52.27 % $ 4.45 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
155 M - -11.76 % $ 5.79 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
619 M - - $ 546 M usaUSA
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Avid Bioservices Avid Bioservices
CDMO
337 M - - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
513 M $ 12.36 -11.46 % $ 1.88 B usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
638 M $ 6.39 3.06 % $ 1.08 B singaporeSingapore
Xenetic Biosciences Xenetic Biosciences
XBIO
8.36 M $ 2.78 -0.71 % $ 4.73 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
8.19 B - 0.49 % $ 251 B cayman-islandsCayman-islands
XBiotech XBiotech
XBIT
150 M $ 2.27 -1.73 % $ 69.2 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
798 M $ 54.44 -1.96 % $ 4.24 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
384 M $ 5.41 -2.87 % $ 868 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
290 M $ 4.07 -5.57 % $ 172 M usaUSA
Xencor Xencor
XNCR
875 M $ 11.4 -7.43 % $ 846 M usaUSA
XOMA Corporation XOMA Corporation
XOMA
273 M $ 29.93 -1.97 % $ 362 M usaUSA
22nd Century Group 22nd Century Group
XXII
27 M $ 2.41 -18.03 % $ 444 K usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
325 M - -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
126 M - -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
426 M - - $ 3.74 B usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
27.7 M $ 1.06 -2.75 % $ 21.7 M israelIsrael
Enochian Biosciences Enochian Biosciences
ENOB
8.23 M - - $ 40.5 M usaUSA